Patents by Inventor Mary Keir
Mary Keir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220357343Abstract: Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.Type: ApplicationFiled: December 15, 2021Publication date: November 10, 2022Applicant: GENENTECH, INC.Inventors: Lauri Diehl, Mary Keir, Meina Tao Tang, Xiaohui Wei, Marna B. Williams
-
Publication number: 20220186314Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: January 20, 2022Publication date: June 16, 2022Applicant: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Patent number: 11261493Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: GrantFiled: April 10, 2020Date of Patent: March 1, 2022Assignee: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Patent number: 11091551Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: GrantFiled: December 18, 2017Date of Patent: August 17, 2021Assignee: Genentech, Inc.Inventors: Mary Keir, Gaik Wei Tew
-
Publication number: 20200325538Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: April 10, 2020Publication date: October 15, 2020Applicant: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Patent number: 10669587Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: GrantFiled: March 7, 2019Date of Patent: June 2, 2020Assignee: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Publication number: 20200025775Abstract: Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.Type: ApplicationFiled: February 28, 2019Publication date: January 23, 2020Applicant: GENENTECH, INC.Inventors: Lauri Diehl, Mary Keir, Meina Tao Tang, Xiaohui Wei, Marna B. Williams
-
Publication number: 20190256913Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: March 7, 2019Publication date: August 22, 2019Applicant: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Patent number: 10273542Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: GrantFiled: September 21, 2016Date of Patent: April 30, 2019Assignee: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Publication number: 20180346576Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: December 18, 2017Publication date: December 6, 2018Applicant: Genentech, Inc.Inventors: Mary Keir, Gaik Wei Tew
-
Patent number: 9873742Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: GrantFiled: March 31, 2015Date of Patent: January 23, 2018Assignee: Genentech, Inc.Inventors: Mary Keir, Gaik Wei Tew
-
Publication number: 20170233809Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: September 21, 2016Publication date: August 17, 2017Applicant: Genentech, Inc.Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
-
Publication number: 20160209426Abstract: Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.Type: ApplicationFiled: September 18, 2015Publication date: July 21, 2016Applicant: GENENTECH, INC.Inventors: Lauri Diehl, Mary Keir, Meina Tao Tang, Xiaohui Wei, Marna B. Williams
-
Publication number: 20160178644Abstract: Biomarkers for diagnosing inflammatory bowel disease, including Crohn's disease, including fibrotic or fibrostenotic Crohn's disease, and ulcerative colitis and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease, including fibrotic or fibrostenotic Crohn's disease, are provided.Type: ApplicationFiled: November 17, 2015Publication date: June 23, 2016Applicant: GENENTECH, INC.Inventors: Jason A. Hackney, Mary Keir, Lilyan Yi Tian Wright
-
Publication number: 20150307611Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.Type: ApplicationFiled: March 31, 2015Publication date: October 29, 2015Applicant: GENENTECH, INC.Inventors: Mary Keir, Gaik Wei Tew